CINECA IRIS Institutional Research Information System

GAMBINO, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.951
EU - Europa 11.471
AS - Asia 9.711
SA - Sud America 669
OC - Oceania 192
AF - Africa 155
Continente sconosciuto - Info sul continente non disponibili 27
Totale 39.176
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.126
CN - Cina 5.512
IT - Italia 2.022
IE - Irlanda 1.207
SE - Svezia 1.192
FR - Francia 1.108
DE - Germania 1.094
SG - Singapore 1.068
UA - Ucraina 766
FI - Finlandia 743
KR - Corea 694
JP - Giappone 685
GB - Regno Unito 653
AT - Austria 520
DK - Danimarca 520
PL - Polonia 440
CA - Canada 419
IN - India 359
MX - Messico 356
VN - Vietnam 318
ES - Italia 311
BR - Brasile 300
ID - Indonesia 189
TW - Taiwan 168
AU - Australia 167
HK - Hong Kong 163
RU - Federazione Russa 156
TR - Turchia 153
NL - Olanda 119
BE - Belgio 117
GR - Grecia 104
PE - Perù 86
CO - Colombia 82
TH - Thailandia 74
CL - Cile 69
IR - Iran 63
RO - Romania 63
PT - Portogallo 61
CH - Svizzera 58
EC - Ecuador 57
AR - Argentina 54
CZ - Repubblica Ceca 41
EG - Egitto 41
MY - Malesia 39
PH - Filippine 39
SI - Slovenia 36
IL - Israele 33
NO - Norvegia 28
SN - Senegal 28
EU - Europa 26
SA - Arabia Saudita 22
HU - Ungheria 21
BY - Bielorussia 20
NZ - Nuova Zelanda 19
GT - Guatemala 15
ZA - Sudafrica 15
IQ - Iraq 14
PK - Pakistan 14
RS - Serbia 14
AE - Emirati Arabi Uniti 13
QA - Qatar 12
SK - Slovacchia (Repubblica Slovacca) 12
TN - Tunisia 11
VE - Venezuela 11
JO - Giordania 9
BG - Bulgaria 8
CV - Capo Verde 8
ET - Etiopia 8
UZ - Uzbekistan 8
BO - Bolivia 7
DZ - Algeria 7
KE - Kenya 7
LV - Lettonia 7
MM - Myanmar 7
MU - Mauritius 7
MV - Maldive 7
AZ - Azerbaigian 6
CR - Costa Rica 6
GH - Ghana 6
HN - Honduras 6
HR - Croazia 6
LT - Lituania 6
PA - Panama 6
AN - Antille olandesi 5
BD - Bangladesh 5
KZ - Kazakistan 5
LB - Libano 5
LK - Sri Lanka 5
SY - Repubblica araba siriana 5
MA - Marocco 4
BA - Bosnia-Erzegovina 3
BF - Burkina Faso 3
CY - Cipro 3
EE - Estonia 3
JM - Giamaica 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
PG - Papua Nuova Guinea 3
PS - Palestinian Territory 3
SV - El Salvador 3
Totale 39.136
Salva come PNG Salva come JPEG
Città #
Beijing 1.896
Chandler 1.603
Ann Arbor 1.198
Dublin 1.194
Fairfield 852
Singapore 793
Houston 765
Santa Clara 661
Ashburn 649
Villeurbanne 645
Woodbridge 594
Wilmington 574
Princeton 490
Vienna 481
Redwood City 473
Jacksonville 441
Dearborn 425
Torino 423
Shanghai 400
Medford 390
Seattle 364
Nyköping 357
Warsaw 336
Pisa 310
Columbus 309
Cambridge 298
Guangzhou 268
Dong Ket 219
Nanjing 215
Hangzhou 200
Boston 157
Tokyo 157
Boardman 138
Fremont 133
Milan 132
Jakarta 125
Ottawa 124
Wuhan 118
Turin 116
Taipei 110
Chengdu 107
Helsinki 89
Chongqing 85
Toronto 83
Pune 82
Hefei 78
Rome 78
Shenyang 76
Norwalk 75
Munich 69
Changsha 68
New York 67
Tianjin 67
Jinan 66
Kunming 66
London 66
Los Angeles 63
San Diego 62
Verona 59
Zhengzhou 57
Menlo Park 55
Lima 54
Phoenix 52
Washington 49
Brussels 48
Falls Church 48
Changchun 46
Frankfurt am Main 45
Istanbul 45
Seoul 45
São Paulo 45
Santiago 44
Xian 44
Central 40
Hong Kong 39
Fuzhou 37
Madrid 35
Nanchang 35
Düsseldorf 34
Mexico City 34
Bogotá 32
Duncan 32
Paris 32
Chicago 31
Mumbai 31
Silver Spring 31
Central District 30
Athens 29
Mexico 29
Barcelona 28
Saint-hubert 28
Mountain View 27
Harbin 26
Berlin 25
Xiamen 25
Montréal 23
Buenos Aires 22
Hyderabad 22
Saint Petersburg 22
Sydney 22
Totale 22.017
Salva come PNG Salva come JPEG
Nome #
Diabetic ketoacidosis with SGLT2 inhibitors 2.529
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. 1.574
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 1.105
Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis 913
Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities 828
Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial 781
Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2×2 factorial randomized trial 730
Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. 687
Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders 565
Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice 529
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. 512
Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation 431
New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease 367
Diabetes-specific variables associated with quality of life changes in young diabetic people: the type 1 diabetes Registry of Turin (Italy) 363
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease 314
Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances 290
Emerging molecular targets for the treatment of nonalcoholic fatty liver disease 290
Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution 282
Impaired taste sensation in type 2 diabetic patients without chronic complications: a case-control study 267
Contributors to the obesity and hyperglycemia epidemics. A prospective study in a population-based cohort. 257
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial 243
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis 235
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. 229
Dietary flavonoid intake and cardiovascular risk: a population-based cohort study 220
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 219
Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: A 12-year follow-up population-based cohort study 205
Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. 200
Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM) 196
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials 196
Acute assessment of subjective appetite and implicated hormones after a hypnosis-induced hallucinated meal: a randomized cross-over pilot trial 195
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 192
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis 191
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy 190
Ruolo protettivo del recettore CB2 nella nefropatia diabetica sperimentale 185
Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria. 185
Protective role of cannabinoid receptor type-2 in a mouse model of diabetic nephropathy 184
Espressione delle proteine dello slit DIAPHRAGM in animali diabetici knockout per il monocyte chemoattractant protein-1. 182
In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control 179
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 179
Effect of the MCP-1/CCR2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes 176
ATTIVAZIONE DEL RECETTORE CB2 E NEFROPATIA DIABETICA SPERIMENTALE 174
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 174
Lipoprotein(a) after acute exercise in healthy subjects. 170
Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. 168
Effect of CB2 Receptor Activation in Experimental Diabetic Nephropathy 167
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 167
High-normal blood pressure and impaired renal function. A prospective study in a population-based cohort. 166
Gender specific medicine in liver diseases: a point of view. 165
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 161
Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation 160
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 155
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 153
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 151
The rs553668 polymorphism of ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study 151
Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up 151
Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography. 149
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH 149
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 149
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 149
Targeting mitochondrial pyruvate carrier in nonalcoholic steatohepatitis: Growing evidence and future challenges. 147
Relationships between human serum resistin, inflammatory markers and insulin resistance 146
The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM) 146
Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. 145
Dietary habits and their relations to insulin sensitivity in non-alcoholic steatohepatitis. 142
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 141
Characterization and representative structures of N-oligosaccharides bound to apolipoprotein H. 139
Metabolic handling of an oral fat load in NAFLD patients. 138
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 137
Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? 136
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 136
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 134
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 133
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 132
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. 131
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 129
Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial 129
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 128
Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? 128
Transcription factor 7-like 2 (TCF7L2) polymorphism and hyperglycemia in an adult Italian population-based cohort. 127
Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 127
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 126
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 126
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 121
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 118
Dietary interventions modify the gut microbiota during pregnancy in patients with gestational diabetes mellitus (GDM) 118
The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. 118
Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort 117
Nel soggetto normale la ferritemia correla con l’HOMA. 117
Acute effects of a hallucinatory meal on subjective appetite and food intake: A randomized cross-over pilot trial 117
Adiponectin gene polymorphism modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH 116
Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study. 116
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII. 115
Non-alcoholic fatty liver disease from pathogenesis to management: an update. 115
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 115
Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy 115
Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications 114
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 112
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 111
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 111
Phytosterol-Enriched Yogurt Increases LDL Affinity and Reduces CD36 Expression in Polygenic Hypercholesterolemia 109
Totale 25.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.413
article - articoli 0
book - libri 0
conference - conferenze 32.522
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 130.935
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.782 0 0 0 0 0 873 621 418 503 529 403 435
2020/20214.459 522 274 234 272 382 321 368 221 423 508 334 600
2021/20225.339 263 369 320 417 346 293 452 381 331 447 828 892
2022/20236.157 723 435 194 521 517 1.406 557 431 531 204 318 320
2023/20244.283 442 507 306 325 341 513 307 291 80 326 380 465
2024/20253.941 337 563 508 676 1.454 403 0 0 0 0 0 0
Totale 40.387